Results for tag: "Recombinant Plasma Protein Drugs"

In biopharmaceuticals, the recombinant plasma protein drugs market comprises a segment focused on therapies derived from human plasma proteins that have been genetically engineered. These drugs are produced using recombinant DNA technology, wherein genes coding for therapeutic plasma proteins are inserted into bacterial, yeast, or mammalian cells, which then act as factories to produce the proteins. This sector addresses a variety of medical conditions and includes proteins such as clotting factors for hemophilia, immunoglobulins for immune disorders, and albumin for maintaining blood volume. By manufacturing these proteins recombinantly, a higher degree of purity and supply security is achieved compared to direct extraction from human plasma. Recombinant plasma protein medications are essential in treating diseases that have limited therapeutic options, offering alternatives with reduced risk of transmitting blood-borne pathogens. Several companies lead in the production and distribution of recombinant plasma protein drugs. Prominent players in this sector include Roche, CSL Behring, and Shire (now part of Takeda Pharmaceuticals). Bayer is well-known for its work on clotting factors, while Biogen focuses on therapies for hematologic and neurodegenerative conditions. Pfizer and Novo Nordisk are other key market participants delivering innovative treatments within the therapeutic plasma protein field. These companies are engaged in intensive research and development to expand the scope of recombinant plasma protein therapies, aiming to address unmet medical needs and improve patient outcomes. Show Less Read more